Phase 2 Trial of Induction With Ixazomib, Pomalidomide, Dexamethasone Prior to Salvage Autologous Stem Cell Transplant Followed by Consolidation With Ixazomib, Pomalidomide, and Dexamethasone and Ixazomib Maintenance in Multiple Myeloma
Latest Information Update: 25 Sep 2023
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 12 Jun 2023 Status changed from active, no longer recruiting to completed.
- 14 Jul 2022 Planned End Date changed from 24 Jul 2022 to 24 Jul 2023.
- 06 Apr 2021 Planned primary completion date changed from 24 Jul 2022 to 1 May 2021.